The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer.
Keunchil Park
No relevant relationships to disclose
Jong-Mu Sun
No relevant relationships to disclose
Sang-We Kim
No relevant relationships to disclose
Myung-ju Ahn
No relevant relationships to disclose
Jin Seok Ahn
No relevant relationships to disclose
Dae Ho Lee
No relevant relationships to disclose
Cheolwon Suh
No relevant relationships to disclose
Yong Chan Ahn
No relevant relationships to disclose
Hongryull Pyo
No relevant relationships to disclose
Eun Kyung Choi
No relevant relationships to disclose
Si Yeol Song
No relevant relationships to disclose
Se-Hoon Lee
No relevant relationships to disclose
Jung Shin Lee
No relevant relationships to disclose